AD affects about 7.2 million Americans aged 65 and older—roughly 11% of that group—and prevalence is rising with population aging. The economic burden is equally stark, with health and long-term care costs estimated at $384 billion in 2025, plus another $413 billion in unpaid caregiver support from nearly 12 million people.

Despite the scale of need, early-stage AD remains underdiagnosed. In many cases, the report highlights that the interval from symptom onset to diagnosis averages 3.5 years. That delay can limit patient access to disease-modifying therapies and slows time-sensitive care planning.

Research featured in the report also points to persistent diagnostic inequities. Only about 8–11% of mild cognitive impairment cases are identified early, and underdiagnosis disproportionately affects Black and Hispanic populations—underscoring the need for more systematic screening approaches.

New diagnostic technology is beginning to close gaps. Blood-based biomarker testing is becoming more accessible in primary care, offering a less invasive route to detecting AD pathology than approaches such as PET imaging or cerebrospinal fluid analysis.

Digital cognitive assessments are also gaining traction. When integrated with electronic health records, these tools may reduce administrative friction while enabling more consistent, scalable screening in routine visits.

The report underscores evidence connecting modifiable lifestyle factors to brain health. The US POINTER randomized clinical trial found that structured, multidomain interventions—combining exercise, diet, cognitive engagement, and social activity—produce greater cognitive benefits than self-guided strategies.

It also links outcomes to practical determinants such as sleep quality, oral health, and food security, noting measurable associations with dementia risk and cognitive decline trajectories.

The report further warns of a post-diagnosis support shortfall. While assistance increases after diagnosis, disability needs often rise faster than available services, especially for instrumental activities of daily living like medication and finances. It calls for ongoing functional reassessment and stronger care coordination with community resources.

Finally, the report frames clinician action as feasible: normalize brain-health discussions, incorporate cognitive screening into standard care, and connect patients and families to interventions early—turning emerging science into timely clinical practice.

Subject of Research: Early detection and management of cognitive decline and Alzheimer’s disease in primary care
Article Title: Understanding Breakthroughs in Brain Health: Top 10 Articles of 2025
News Publication Date: 2025
Web References: https://gsaenrich.geron.org/files/a225fff1-1760-4d8b-9b6f-e8fb62045d90
References: U.S. POINTER randomized clinical trial (as cited in the report)
Image Credits: Not provided
Keywords: Alzheimer’s disease, dementia, primary care, early detection, blood biomarkers, digital cognitive assessment, lifestyle intervention, cognitive decline, care coordination

Traditionally, memory disturbances have dominated the diagnostic criteria for dementia, overshadowing a host of other cognitive alterations. However, the authors present mounting empirical evidence indicating that attentional changes are not only pervasive across various dementia subtypes but may also manifest prior to memory deficits. This insight is pivotal, suggesting that current diagnostic methods—heavily reliant on memory testing—may overlook subtle yet critical early signs of cognitive decline rooted primarily in attentional dysfunction. By advocating for an attentional framework, the book paves the way for more sensitive and accurate early diagnostics, which is vital for timely intervention strategies.

The volume meticulously explores the intricate synergy between attention and executive functions. It delineates how automatic and controlled cognitive processes undergo transformation during the progression of dementia. In this context, the authors elucidate that attention is not a monolithic faculty but a constellation of interrelated subprocesses susceptible to heterogeneous disruption. Such nuanced understanding is crucial for both clinicians and researchers aiming to map the trajectory of cognitive decline with greater precision.

Delving deeper, the text grapples with the conceptual ambiguity surrounding “attention” itself. Drawing upon classical cognitive theories, the authors examine historical interpretations alongside everyday language usage of attention, juxtaposed with contemporary neuropsychological models and cognitive neuroscience data. This multi-faceted investigation underscores the importance of defining attention with rigor to effectively leverage it as a clinical biomarker and therapeutic target.

Importantly, the book features a unique chapter that weaves in experiential perspectives — a caregiver’s narrative that contextualizes theoretical constructs of attention impairment within the realities of daily life affected by dementia. This inclusion bridges the gap between empirical science and lived experience, enriching the discourse with poignant human insight that is often marginalized in academic texts.

Another innovative dimension introduced in the book is the consideration of attention restoration theory, highlighting the potential of natural environments in ameliorating attentional overload. By incorporating environmental psychology into the dementia conversation, the authors open promising avenues for non-pharmacological interventions, which could mitigate cognitive symptoms and enhance quality of life for individuals grappling with attentional deficits.

The collaborative nature of this project is equally remarkable. Conceived by Professor Tales, the book represents a concerted effort that brings together colleagues and former students, fostering a vibrant academic lineage centered on cognitive dysfunction in dementia. This approach exemplifies the potency of sustained scholarly partnerships in driving forward complex interdisciplinary fields and mentoring emerging researchers in translating nuanced science into accessible, impactful publications.

Expanding on this momentum, the group is committed to producing a series of volumes aiming to reshape dementia research and clinical paradigms. Their second book built upon sensory and perceptual change themes, developed in concert with people living with dementia and their caregivers—an approach exemplifying participatory research models. Now, with a third volume focusing on technological applications in dementia care underway, the series is poised to continuously influence multiple facets of dementia understanding and management.

Co-author Dr. Clive Thomas, a strategic program manager for mental health in NHS Wales, emphasizes the real-world clinical implications emerging from this collaboration. His testimony underscores a critical tension between entrenched memory-centric diagnostic paradigms and the dynamic realities clinicians face. The partnership elucidates why shifting diagnostic focus towards early attentional symptoms is not merely academic but a necessity for evolving effective health care practices and policies that address the complex spectrum of dementia.

The book’s synthesis of foundational theory, clinical relevance, and authentic caregiving experience presents a comprehensive and compelling case for reorienting dementia science around attentional mechanisms. This is not only a modest academic contribution but a clarion call for profound systemic change, challenging stakeholders across scientific, medical, and caregiving communities to rethink the constructs that have long defined dementia.

By bringing attention impairments to the forefront, A New Approach to Dementia catalyzes new investigative priorities, therapeutic strategies, and healthcare innovations that promise enhanced detection accuracy and improved quality of care. As dementia incidence escalates globally with aging populations, such a recalibration of scientific focus is both timely and urgent, bearing meaningful implications for millions affected by neurodegenerative diseases worldwide.

This transformative volume is available now via Taylor & Francis, providing researchers, clinicians, and caretakers access to a visionary framework that could alter the course of dementia research and patient outcomes. It signals an exciting frontier in cognitive neuroscience and neuropsychology, spotlighting attentional dynamics as a critical, yet underappreciated, axis in understanding and managing dementia.

Subject of Research: Attention impairments in dementia and their clinical implications
Article Title: A New Approach to Dementia: Examining Attention Impairment
News Publication Date: Not specified
Web References: https://www.taylorfrancis.com/books/edit/10.4324/9781003610953/new-approach-dementia-andrea-tales-clive-thomas-kimberley-littlemore-rowan-brown
Keywords: Dementia, attention impairment, cognitive disorders, neuropsychology, early diagnosis, executive function, cognitive neuroscience, caregiving, attentional mechanisms, attention restoration theory, neurodegenerative diseases, healthcare innovation